AIRLINK 72.99 Decreased By ▼ -1.11 (-1.5%)
BOP 5.04 Increased By ▲ 0.04 (0.8%)
CNERGY 4.37 Increased By ▲ 0.03 (0.69%)
DFML 30.08 Increased By ▲ 0.54 (1.83%)
DGKC 84.15 Increased By ▲ 0.60 (0.72%)
FCCL 22.32 Decreased By ▼ -0.11 (-0.49%)
FFBL 34.02 Decreased By ▼ -0.88 (-2.52%)
FFL 10.26 Increased By ▲ 0.39 (3.95%)
GGL 10.35 Increased By ▲ 0.35 (3.5%)
HBL 112.00 No Change ▼ 0.00 (0%)
HUBC 140.40 Increased By ▲ 2.71 (1.97%)
HUMNL 8.03 Increased By ▲ 1.05 (15.04%)
KEL 4.36 Decreased By ▼ -0.04 (-0.91%)
KOSM 4.60 Increased By ▲ 0.01 (0.22%)
MLCF 38.55 No Change ▼ 0.00 (0%)
OGDC 135.30 Decreased By ▼ -1.30 (-0.95%)
PAEL 26.65 Increased By ▲ 1.51 (6.01%)
PIAA 26.00 Decreased By ▼ -0.51 (-1.92%)
PIBTL 6.64 Decreased By ▼ -0.01 (-0.15%)
PPL 122.42 Decreased By ▼ -2.98 (-2.38%)
PRL 28.21 No Change ▼ 0.00 (0%)
PTC 13.80 Decreased By ▼ -0.50 (-3.5%)
SEARL 55.00 Increased By ▲ 0.40 (0.73%)
SNGP 70.20 Decreased By ▼ -1.00 (-1.4%)
SSGC 10.48 Decreased By ▼ -0.02 (-0.19%)
TELE 8.67 Increased By ▲ 0.15 (1.76%)
TPLP 11.00 Increased By ▲ 0.06 (0.55%)
TRG 62.00 Increased By ▲ 1.30 (2.14%)
UNITY 25.25 Decreased By ▼ -0.08 (-0.32%)
WTL 1.30 Increased By ▲ 0.04 (3.17%)
BR100 7,657 Decreased By -7.6 (-0.1%)
BR30 25,068 Increased By 42.7 (0.17%)
KSE100 73,055 Increased By 290.3 (0.4%)
KSE30 23,742 Decreased By -33.9 (-0.14%)
World

Turkey signs 50mn dose COVID-19 vaccine deal

  • We have signed a contract for 50 million doses of vaccines to be delivered in the months of December, January and February.
  • Sinovac's experimental COVID-19 vaccine CoronaVac triggered a quick immune response, but the level of antibodies produced was lower than in people who had recovered from the virus.
Published November 26, 2020

ISTANBUL: Turkey has signed a contract to buy 50 million doses of COVID-19 vaccine from China's Sinovac Biotech, Health Minister Fahrettin Koca said on Wednesday.

"We have signed a contract for 50 million doses of vaccines to be delivered in the months of December, January and February," Koca told a news conference.

Sinovac's experimental COVID-19 vaccine CoronaVac triggered a quick immune response, but the level of antibodies produced was lower than in people who had recovered from the virus, preliminary trial results showed.

CoronaVac and four other experimental vaccines developed in China are in late-stage trials to determine their effectiveness.

Speaking in Ankara after a coronavirus science council meeting, Koca said Turkey is also in talks with other vaccine developers.

"The important thing here for us to start using vaccines which are known to be effective and reliable ... I think the vaccination calendar could start on Dec. 11," Koca also said.

Comments

Comments are closed.